Here are the editors' top picks for the week ended July 6.
IMV CEO: 'Stressful' part is past, fundamental year ahead for Canadian biotech
The Canadian biotech's CEO discussed the company's recent data, listing and name change, as well as its looming milestones.
Democrats probe US health chief's blame of middlemen for high drug prices
Two senators are probing recent claims by U.S. Department of Health and Human Services Secretary Alex Azar that drugmakers want to make "substantial and material" price reductions but are being thwarted by middlemen seeking higher rebates.
New clot-busting drugs linked to lower risk of serious bleeding, study shows
Newer anti-clotting drugs such as Bristol-Myers Squibb Co.'s Eliquis cause less risk of a major bleeding episode than warfarin, the oral anticoagulant developed 70 years ago, a new study published in the British Medical Journal showed.
Roche's Tecentriq shows promise against an aggressive breast cancer, study shows
Roche Holding AG said Tecentriq taken in combination with chemotherapy prolonged life and cut the risk of a rare type of breast cancer progressing, marking the third recent win for the immuno-oncology medicine.
Capitol Checkup: US self-inflicted costs; Kentucky blocked; defensive internet
Senators probe what is driving U.S. healthcare costs; court blocks Kentucky Medicaid work requirement; and the Food and Drug Administration's chief said internet companies are helpful, but defensive in the effort to halt online opioid sales.
Novartis to spin off Alcon as CEO continues to streamline, focus on medicines
Novartis AG confirmed plans to spin off its Alcon eye care unit as the new CEO Vas Narasimhan continues to streamline the Swiss pharmaceuticals company and focus on medicines.